[go: up one dir, main page]

SI3535397T1 - Ligandi alfa-V beta-6 integrina in njihove uporabe - Google Patents

Ligandi alfa-V beta-6 integrina in njihove uporabe

Info

Publication number
SI3535397T1
SI3535397T1 SI201731066T SI201731066T SI3535397T1 SI 3535397 T1 SI3535397 T1 SI 3535397T1 SI 201731066 T SI201731066 T SI 201731066T SI 201731066 T SI201731066 T SI 201731066T SI 3535397 T1 SI3535397 T1 SI 3535397T1
Authority
SI
Slovenia
Prior art keywords
beta
alpha
integrin ligands
integrin
ligands
Prior art date
Application number
SI201731066T
Other languages
English (en)
Inventor
Aaron Almeida
Zhen Li
Erik W Bush
Tao Pei
Angieszka Glebocka
Anthony Nicholas
Jeffrey Carlson
Matthew Fowler-Watters
Original Assignee
Arrowhead Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals, Inc. filed Critical Arrowhead Pharmaceuticals, Inc.
Publication of SI3535397T1 publication Critical patent/SI3535397T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3513Protein; Peptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
SI201731066T 2016-11-01 2017-11-01 Ligandi alfa-V beta-6 integrina in njihove uporabe SI3535397T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662415752P 2016-11-01 2016-11-01
EP17867252.3A EP3535397B1 (en) 2016-11-01 2017-11-01 Alpha-v beta-6 integrin ligands and uses thereof
PCT/US2017/059550 WO2018085415A1 (en) 2016-11-01 2017-11-01 Alpha-v beta-6 integrin ligands and uses thereof

Publications (1)

Publication Number Publication Date
SI3535397T1 true SI3535397T1 (sl) 2022-04-29

Family

ID=62076333

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731066T SI3535397T1 (sl) 2016-11-01 2017-11-01 Ligandi alfa-V beta-6 integrina in njihove uporabe

Country Status (22)

Country Link
US (2) US11180529B2 (sl)
EP (2) EP3535397B1 (sl)
JP (3) JP7291624B2 (sl)
KR (1) KR102634762B1 (sl)
CN (2) CN117285626A (sl)
AU (2) AU2017354041B2 (sl)
BR (1) BR112019008965A2 (sl)
CA (1) CA3039618A1 (sl)
DK (1) DK3535397T3 (sl)
EA (1) EA201991102A1 (sl)
ES (1) ES2906109T3 (sl)
HR (1) HRP20220181T1 (sl)
IL (2) IL305158A (sl)
JO (1) JOP20190084B1 (sl)
MX (3) MX2019004909A (sl)
NZ (1) NZ751843A (sl)
PL (1) PL3535397T3 (sl)
SA (1) SA519401709B1 (sl)
SI (1) SI3535397T1 (sl)
TW (1) TWI776821B (sl)
WO (1) WO2018085415A1 (sl)
ZA (2) ZA201901905B (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ751843A (en) * 2016-11-01 2025-05-02 Arrowhead Pharmaceuticals Inc Alpha-v beta-6 integrin ligands and uses thereof
IL297530B2 (en) 2017-02-28 2025-04-01 Morphic Therapeutic Inc (Alpha–V)(beta–6) integrin inhibitors
AU2018227417B2 (en) 2017-02-28 2021-12-23 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
PE20200746A1 (es) 2017-07-06 2020-07-24 Arrowhead Pharmaceuticals Inc AGENTES DE iARN PARA LA INHIBICION DE LA EXPRESION DE ALFA-ENAC Y METODOS DE USO
EP4086254B1 (en) 2018-08-29 2024-12-18 Morphic Therapeutic, Inc. Integrin inhibitors
KR102663798B1 (ko) 2019-06-25 2024-05-03 주식회사 엘지에너지솔루션 배터리 시스템
CA3189071A1 (en) * 2020-09-11 2022-03-17 Xiaokai Li Skeletal muscle delivery platforms and methods of use
CA3189081A1 (en) * 2020-09-11 2022-03-17 Xiaokai Li Integrin targeting ligands and uses thereof
MX2023002853A (es) 2020-09-11 2023-03-31 Arrowhead Pharmaceuticals Inc Agentes de arni para inhibir la expresion de dux4, composiciones de dichos agentes, y metodos de uso.
WO2022251394A1 (en) 2021-05-28 2022-12-01 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of mucin 5ac (muc5ac), compositions thereof, and methods of use
EP4547683A2 (en) 2022-06-30 2025-05-07 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
JP2003530871A (ja) * 2000-04-21 2003-10-21 アムジエン・インコーポレーテツド インテグリン/接着因子アンタゴニスト
DE10118550A1 (de) * 2001-04-14 2002-10-17 Merck Patent Gmbh Liganden des Integrins alpha¶nu¶beta¶6¶
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
BRPI0715141A2 (pt) * 2006-08-03 2013-06-04 Astrazeneca Ab agente de ligaÇço alvejante, anticorpo isolado, fragmento de anticorpo isolado, molÉcula de Ácido nucleico, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para produzir um anticorpo, para produzir um fragmento de anticorpo, para tratar um tumor maligno em um animal, para tratar inflamaÇço, e para inibir a interaÇço de alfabeta6 com seu ligando, e, conjugado
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
EP2221334B1 (en) 2007-11-28 2016-12-28 FUJIFILM Corporation Method for chemically modifying biopolymer and polypeptide
AU2011333666B2 (en) * 2010-11-26 2017-02-02 Molecular Partners Ag Improved capping modules for designed ankyrin repeat proteins
CN105017420B (zh) * 2012-02-17 2019-05-28 西雅图基因公司 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
EP3131566B1 (en) * 2014-04-15 2022-10-05 The Regents of the University of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
US10073109B2 (en) * 2015-04-06 2018-09-11 The Board Of Regents Of The University Of Oklahoma Phages of biomarker capture and methods of use
EP3130912B1 (de) 2015-08-14 2017-06-28 Sick Ag Verfahren zur bestimmung der konzentration einer gaskomponente und spektrometer dafür
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
NZ751843A (en) * 2016-11-01 2025-05-02 Arrowhead Pharmaceuticals Inc Alpha-v beta-6 integrin ligands and uses thereof

Also Published As

Publication number Publication date
MX2023007046A (es) 2023-06-23
EP3535397A1 (en) 2019-09-11
JOP20190084A1 (ar) 2019-04-16
IL305158A (en) 2023-10-01
TW201829445A (zh) 2018-08-16
MX2023007051A (es) 2023-06-23
AU2017354041B2 (en) 2024-02-01
NZ751843A (en) 2025-05-02
KR20190075937A (ko) 2019-07-01
AU2017354041A1 (en) 2019-04-11
JP2023105046A (ja) 2023-07-28
AU2024202695A1 (en) 2024-05-16
HRP20220181T1 (hr) 2022-04-29
JP2019535685A (ja) 2019-12-12
KR102634762B1 (ko) 2024-02-06
EA201991102A1 (ru) 2019-09-30
EP3535397B1 (en) 2022-01-05
JP2025107348A (ja) 2025-07-17
CN117285626A (zh) 2023-12-26
JOP20190084B1 (ar) 2023-09-17
MX2019004909A (es) 2019-08-12
US12173086B2 (en) 2024-12-24
IL266343B2 (en) 2024-01-01
BR112019008965A2 (pt) 2019-07-09
PL3535397T3 (pl) 2022-03-07
DK3535397T3 (da) 2022-01-31
CN109952376B (zh) 2023-09-05
CA3039618A1 (en) 2018-05-11
WO2018085415A1 (en) 2018-05-11
SA519401709B1 (ar) 2023-06-04
IL266343B1 (en) 2023-09-01
EP3535397A4 (en) 2020-06-03
ZA202203240B (en) 2024-06-26
IL266343A (en) 2019-06-30
US11180529B2 (en) 2021-11-23
ZA201901905B (en) 2022-11-30
EP3981780A1 (en) 2022-04-13
CN109952376A (zh) 2019-06-28
JP7291624B2 (ja) 2023-06-15
US20190248832A1 (en) 2019-08-15
TWI776821B (zh) 2022-09-11
ES2906109T3 (es) 2022-04-13
US20220024975A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
ZA202203240B (en) Alpha-v beta-6 integrin ligands and uses thereof
SG11202002967SA (en) Integrin ligands and uses thereof
IL272330A (en) Anti-CD47 antibodies and uses thereof
SG11201808632YA (en) Anti-pacap antibodies and uses thereof
SG10202007176TA (en) Anti-cd47 antibodies and uses thereof
IL248947B (en) Antagonists for a4b7 integrin thioether peptide
ZA201901935B (en) Anti-il-33 antibodies and uses thereof
IL262010A (en) Anti-complement factor bb antibodies and their uses
IL266049A (en) Antibodies against o1 and their uses
IL266082A (en) Anti-chikv antibodies and their use
IL264417A (en) Anti-o2 antibodies and their uses
IL258863A (en) Integrin-binding peptides and their use
GB201603311D0 (en) New uses and methods
GB2548839B (en) New uses and methods
EP3279378A4 (en) Airbag-use woven fabric and airbag
SG11201912432VA (en) Emm-23 materials and processes and uses thereof
GB201615254D0 (en) Novel Ligand and use thereof
SI3350222T1 (sl) Ligandi za integrin avbeta6, sinteza in uporaba le-teh
HK40014552A (en) Alpha-v beta-6 integrin ligands and uses thereof
SG11202005282VA (en) Emm-31 materials and processes and uses thereof
HK40033843A (zh) 整聯蛋白配體及其用途
GB201710941D0 (en) Ligands and catalysts
GB2549557B (en) Bucket-tidy and method of organising items held within a bucket
GB201619935D0 (en) Heterogenneous catalyst and uses thereof